Novel HER2 selective tyrosine kinase inhibitor, TAK‐165, inhibits bladder, kidney and androgen‐independent prostate cancer in vitro and in vivo
暂无分享,去创建一个
Mikio Namiki | Atsushi Mizokami | Sei Yoshida | A. Mizokami | M. Namiki | Sei Yoshida | J. Nagasawa | K. Koshida | Kenichiro Naito | Joji Nagasawa | Kiyoshi Koshida | Kenichiro Naito
[1] M. Brattain,et al. Synergy of epidermal growth factor receptor kinase inhibitor AG1478 and ErbB2 kinase inhibitor AG879 in human colon carcinoma cells is associated with induction of apoptosis. , 2005, Cancer research.
[2] J. Montie. Her-2/neu protein overexpression and gene amplification in human transitional cell carcinoma of the bladder. , 2005, The Journal of urology.
[3] Y. Kajiyama,et al. Monoclonal antibody to HER-2/neu receptor enhances radiosensitivity of esophageal cancer cell lines expressing HER-2/neu oncoprotein. , 2005, International journal of radiation oncology, biology, physics.
[4] E. Crawford,et al. The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial , 2004, The Prostate.
[5] J. Lloreta,et al. Her-2/neu Expression in Prostate Cancer , 2004, Clinical Cancer Research.
[6] Tomoaki Tanaka,et al. Effect of type I growth factor receptor tyrosine kinase inhibitors on phosphorylation and transactivation activity of the androgen receptor in prostate cancer cells: Ligand-independent activation of the N-terminal domain of the androgen receptor. , 2004, Oncology reports.
[7] J. Doroshow,et al. Trastuzumab plus docetaxel in HER‐2/neu‐positive prostate carcinoma , 2004, Cancer.
[8] T. R. Griffiths,et al. Tyrosine kinase inhibitors of the epidermal growth factor receptor as adjuncts to systemic chemotherapy for muscle-invasive bladder cancer. , 2004, Urology.
[9] M. Peyromaure,et al. Management of primary resistance to gemcitabine and cisplatin (G-C) chemotherapy in metastatic bladder cancer with HER2 over-expression. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[10] L. Crinò,et al. Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer , 2004, British Journal of Cancer.
[11] Lesley Seymour,et al. Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. , 2003, The Lancet. Oncology.
[12] Masahiro Fukuoka,et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] G. Hortobagyi,et al. Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells. , 2002, Cancer research.
[14] John F Timms,et al. Effects of ErbB-2 overexpression on mitogenic signalling and cell cycle progression in human breast luminal epithelial cells , 2002, Oncogene.
[15] K. Wester,et al. HER-2 - A Possible Target for Therapy of Metastatic Urinary Bladder Carcinoma , 2002, Acta oncologica.
[16] M. Piccart-Gebhart. Herceptin®: the future in adjuvant breast cancer therapy , 2001, Anti-cancer drugs.
[17] S. Groshen,et al. Her-2/neu expression in prostate cancer: high level of expression associated with exposure to hormone therapy and androgen independent disease. , 2001, The Journal of urology.
[18] M. Sliwkowski,et al. Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth. , 2001, Gastroenterology.
[19] Monilola A. Olayioye,et al. The ErbB signaling network: receptor heterodimerization in development and cancer , 2000, The EMBO journal.